Biofármacos y terapias dirigidas mediante pequeñas moléculas inmunosupresoras
Renaud Felten(Centre National de la Recherche Scientifique), Jean Sibilia(Immunologie, Immunopathologie et Chimie Thérapeutique), Florence Scher(Hôpitaux Universitaires de Strasbourg), Christelle Sordet, Emmanuel Chatelus(Laboratoire National de Référence), Laurent Arnaud(Université Libre de Bruxelles), J.E. Gottenberg(Inserm), Auriane Mallick(Hopitaux Civils de Colmar), R.‐M. Javier(Hôpitaux Universitaires de Strasbourg), Flora Sagez(Laboratoire National de Référence)
Cited by 1
Related Papers
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease
|New England Journal of Medicine|2018|501
Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review
|Seminars in Arthritis and Rheumatism|2007|456
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
|Annals of the Rheumatic Diseases|2014|432
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)
|Annals of the Rheumatic Diseases|2016|355